They are facing challenges due to logistics, RM availability and higher price – especially for solvents. Most solvent prices were at an all time high. They have started to see some easing in terms of availability and cost of APIs and solvents. However, supply chain and logistics costs continue to be a challenge. Revenue has …
Revenues for the quarter stood at ₹2510 Cr (46% growth YoY). PBT for the quarter stood at ₹1034 Cr (61% growth YoY). Exports contributed to 92% of revenues for the quarter. Europe and the US contributed to 79% of revenues . Generics contributed to 40% and Custom Synthesis contributed to 60% of revenues for the …
Operations were mostly unaffected by COVID. They have observed lengthening of supply chains, so they are stocking up on raw materials for Q4. Revenue growth was 10% YoY. EBITDA growth was 12% indicating operating leverage. Key growth drivers for revenue during the quarter were discovery services and dedicated centers. Development and manufacturing services delivered more …
Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY). Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole. Growth in the API portfolio excluding Albendazole has been …